Abstract:In myeloid malignancies including acute myeloid leukaemia and myelodysplastic syndrome, mutations in spliceosome components drive aberrant RNA splicing and tumourigenesis. Numerous therapeutic strategies have been employed to target this aberrant splicing and achieve splicing‐mutant cell death. Attempted approaches include drugs binding specific spliceosome components, promotion of splicing factor degradation, oligonucleotide therapeutics, and inhibition of splicing factor signalling, methylation, and phosphorylation. Summary In recent years, large‐scale sequencing efforts have identified targetable driver mutations in haematopoietic stem cells. These efforts have led to the development and approval of nine novel agents for relapsed or refractory acute myelogenous leukaemia (R/R AML). However, despite an expansion in targeted therapies, achieving a durable remission in AML and high‐risk myelodysplastic syndrome (HR‐MDS) remains a significant challenge, and there is an urgent need for new effective treatments. Modulation of aberrant RNA splicing has emerged as a novel therapeutic approach in myeloid diseases. Aberrant splicing drives dysregulated gene expression that promotes tumourigenesis through increased proliferation and metastatic potential, immune evasion, decreased apoptosis, and chemotherapy resistance. Mutations in spliceosomal components have been identified in numerous cancer subtypes, with mutations in RNA binding proteins SF3B1, SRSF2, U2AF1, and ZRSR2 occurring frequently in AML and in up to 60% of patients with MDS, as well as in chronic myelomonocytic leukaemia and in 10% of patients with chronic lymphocytic leukaemia. In this review, we explore therapeutic strategies targeting aberrant splicing and the potential of these approaches to drive clinical responses.

Alternative Splicing in Myeloid Malignancies

Biological relevance of alternative splicing in hematologic malignancies

Alternative splicing and cancer: a systematic review

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

Significance of Alternative Splicing in Cancer Cells.

Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia

RNA splicing alterations induce a cellular stress response associated with poor prognosis in AML

Splicing the Difference: Harnessing the complexity of the transcriptome in hematopoiesis

Mutations in Splicing Factor Genes in Myeloid Malignancies: Significance and Impact on Clinical Features

Alternative splicing and related RNA binding proteins in human health and disease

Splicing factors: Insights into their regulatory network in alternative splicing in cancer

The role of alternative splicing in human cancer progression.

Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes

The interplay between non-coding RNAs and alternative splicing: from regulatory mechanism to therapeutic implications in cancer

Mechanisms of non-coding RNA-modulated alternative splicing in cancer

Alternative Splicing of Pre-mRNA Matters in Oral Diseases.

Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies

Epigenetic Regulation of Alternative Splicing.

Alternative Splicing As a Biomarker and Potential Target for Drug Discovery

Alternative pre-mRNA splicing in stem cell function and therapeutic potential: A critical review of current evidence